Author Index to Volume 10

Aldridge, K.E., 31, 221

Balfour Jr., H.H., 149, 205
Barry, A.L., 221
Bartholoma, N.Y., 121
Batchelor, R.A., 135
Beaman, L., 65
Bode, R.B., 165
Body, B.A., 65
Bottone, E.J., 125
Burke, D.S., 103

Carnahan, A.M., 195
Chang, T.-W., 65
Cheung, L.L., 171
Colwell, R.R., 195
Cone, R., 65
Corley, E., 93
Cornick, N.A., 81
Crane, D.D., 149

Damato, J.J., 103
Davis, J.R., 41, 67
Dias, F., 109
Diaz, A., 93
Dirksen, C.L., 149
Doern, G.V., 131
Domingo, C.J., 61

Echevarria, J.M., 61
Echevarria, P., 75
Edelman, C.K., 149, 205
Ehresman, D., 213
Ellis, C., 185
Ellner, P.D., 181
Engler, H.D., 125
Englund, J., 205
Erice, A., 205

Fetchick, R.J., 113
Fipps, D.R., 103
Forbes, B.A., 121
Fuchs, P.C., 221

George, W.L., 57
Gerding, D.N., 85
Gerlach, E.H., 221
Goc, B., 93
Goldstein, E.C.J., 65
Gopaul, D., 185
Gorbach, S.L., 81
von Graevenitz, A., 131
Granato, P.A., 65
Gresser-Burns, M.E., 49, 213

Haake, D.A., 57
Hanchalay, S., 75
Hanff, P.A., 65
Henry, K., 49
Hertz, M.I., 205
Hewitt, W.L., 57
Hoffner, S.E., 1
Holme, T., 7
Hudson, J.B., 171

Jackson, J.B., 65
Johnson, J.E., 159
Jones, R.N., 221
Joseph, M.G., 185
Joseph, S.W., 195

Kaltwasser, G., 145
Kelly, J., 149
Kentala, J.T., 149
Kidd, H., 109
Kramer, E.D., 181
Kumazawa, J., 23

Lally, R.T., 49, 213
Lam, M., 145
Libertin, C.R., 139
Libonati, J.P., 41

Maki, Jr., A., 185
McCuan–Kirsch, C.M., 165
McGouch, D.A., 113
Minagawa, H., 23
Montiel, F., 145
Mori, R., 23

O'Brien, M., 195
Olson, M.M., 85

de Ory, Fernando, 61

Palermo, D.R., 149
Pappagianis, D., 65
Peterson, L.R., 85
Pfaller, M.A., 221
Pueyo, S., 93

Reitano, M., 125
Rhodes, J.C., 165
Rinaldi, M.G., 113
Risling, M., 7
Robertson, J.A., 65
Ryan, R.W., 109

Sagiyama, K., 23
Sakuma, S., 23
Sanders, C.V., 31
Schwartz, J.G., 113
Shanholtzer, C.J., 85
Shapiro, H.M., 191
Siddiqi, S.H., 41, 67
Sjögren, A.M., 7
Snyder, L.S., 205
Stager, C.E., 41, 67
Stein, D.S., 139
Stevens, P.R., 65
Suarez, D.S., 149

Taylor, D.N., 75
Thorne, G.M., 65
Thorner, R.E., 113
Tilton, R.C., 109
Tio, F.O., 113

Valainis, G.T., 31

Washington, II J.A., 221
Wignall, F.S., 135
Woods, G.L., 65
Woolfrey, B.F., 49, 213
Wüst, J., 131

Yaldivieso, C., 145
Yanagi, K., 23

Zorzopulos, J., 93
Zukerman, A.J., 241

© 1988 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0732-8893/89/$03.50

DIAGN MICROBIOL INFECT DIS
1988;10:247–256

Subject Index to Volume 10

Abcesses
  multiple organ, 31
Abdominal pain
  as symptom of *Aeromonas* suppurative thrombophlebitis, 57
2-Acetamido-4-amino-2,4,6-trideoxygalactose (Sug), 7
N-Acetyl-β-D-glucosaminidase, 195
Acid fact bacilli
  Mycobacterium tuberculosis, 41, 67
Acidimetric testing
  Supplement C and, 213
Acidosis
  metabolic, 58
  respiratory, 58
Acquired immunodeficiency syndrome (AIDS)
  CDC surveillance definition for, 1
  HIV as etiological agent for, 103
  Mycobacterium avium complex opportunistic infections in, 1
  pulmonary complications and, 125
  Rhodococcus rhodocrous infection and, 185
Actinomycotic mycetoma, 113
Acyclovir
  for varicella zoster virus, 149
Adonitol, 116
Aeromonas caviae, 59, 195
Aeromonas hydrophila, 58, 196
Aeromonas salmonicida, 59
Aeromonas sobria, 59, 195
Aeromonas spp.
  enzymatic characterization of, 194
  suppurative thrombophlebitis due to, 57
Agar
  blood, 131
  Brucella, 135
  Hektoen enteric, 135
  MacConkey, 131, 135
  Mueller–Hinton, 213
  rose bengal-elastin, 165
  TCBS, 136
  Thayer–Martin, 131
  TSA/AMP, 136
  XLD, 136
  xylose-lysine-desoxycholate, 135
Agar dilution method
  breakpoints, 49
  Neisseria gonorrhoeae and, 49
  Mycobacterium tuberculosis and, 41
Agglutination
  chicken erythrocyte, 136
  latex, for antigen detection, 7
β-Agonists, 57
AIDS. See Acquired immunodeficiency syndrome
L-Alanine, 195
Alcoholism, 131
Alkaline extraction procedure
  human papillomavirus DNA and, 93
Alkaline phosphatase, 136
Amikacin
  for *Aeromonas* suppurative thrombophlebitis, 58
  against *Nocardia brasiliensis*, 117
Aminocyclitols
  against *Nocardia brasiliensis*, 119
Aminoglycosides
  against *Chromobacterium violaceum*, 31
  for endocarditis, 139
  penicillin resistance to, 145
Aminopeptides, 195
Ampicillin
  for *Aeromonas* suppurtative thrombophlebitis, 58
  antagonism and Supplement C, 213
  MICs for, 58, 213
  against *Nocardia brasiliensis*, 117
Animal hepadna viruses, 241
Anogenital condylomata, 24
Antagonists
  β-lactamase in Supplement C, 213
Antibodies
  anti-HIV-1, 103, 158
  anti-phosphorylcholine determinant, 7
  catcher, 8
  fluorescein-conjugated, 125
  gold-labelled, demonstration of cross-reactions between pneumococci and α-streptococci using, 7
  IgA, 75
  IgG, 75
  IgM, 75, 111
  Legionella pneumophila sero group 6, 125
  monoclonal, gold-labelled, 7
  Mycoplasma pneumoniae, 109
  polyclonal, gold-labelled, 7
  screening of to varicella zoster virus in leukemic patients, 61
  varicella zoster virus, 149
Antigens
  cross-reacting of α-streptococci, 7
  detection methods for, 7
  plasmid-encoded, serological response to in patients with shigellosis, 75
  pneumococcal capsular, 8
  polypeptide, 75
  Shigella flexneri M90, 75
  viral, 206
Antimicrobial agent resistance
  in *Neisserria gonorrhoeae*, 49
Antimouse immunogold conjugate, 7
Antisera
  Hikojima, 137
  Inaba, 137
  Neisseria meningitidis, 131
  Ogawa, 137
  papillomavirus, 23
  poly 01, 137
Apalcillin
  against *Chromobacterium violaceum*, 31
API 20E strips, 136
API esterase
  characterization of *Aeromonas* spp. using, 195
API osidase
  characterization of *Aeromonas* spp. using, 195
API peptidase
  characterization of *Aeromonas* spp. using, 195
Arabinose, 116
Argentine population
  incidence of human papillomavirus in skin warts of, 93

© 1988 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0732-8893/89/$03.50

L-Arginine, 195
Arthritis
  temporal, 115
Arylamide, 195
Aspergillosis
  invasive, 165
Aspergillus fumigatus, 165
  DNA, 172
Aspergillus spp.
  elastase production in clinical isolates of, 164
Assays
  dot blot hybridization, 93
  enterotoxin, 136
  enzyme-linked immunosorbent, 159
  HIV Novopath Immunoblot, 159
  immunofluorescence for detection of HIV-1 antibodies, 158
  Y1 adrenal cell, 135
Augmentin
  against *Nocardia brasiliensis*, 117
Aztreonam
  against *Chromobacterium violaceum*, 31

Bacilli
  acid-fast 41, 67
  extracellular, 125
  facultatively anaerobic, 31
  gram-negative, 31, 58, 131, 221
  intracellular, 125
  MOTT, 67
  oxidase-positive, 31
  slender vialaceous, 125
Bacillus subtilis
  DNA, 172
Bactec 12a medium, 67
Bactec NAP vial
  identification of *Mycobacterium tuberculosis* in sputum by direct inoculation of, 67
Bactec radiometric system
  detection of *Mycobacterium avium* complex with, 1
  direct antimicrobial drug susceptibility testing of *Mycobacterium tuberculosis* by, 41
Bacteremia
  Aeromonas spp.-caused, 57
  group C *Streptococcus*-caused, 181
Bacterial
  cells, immunogold labelling of, 7
  meningitis, *Streptococcus pneumoniae* as pathogen in, 7
Bacteroides caccae, 81
Bacteroides distasonis, 81
Bacteroides fragilis group
  synergistic activity of cefoxatime and desacetylcefoxatime against, 81
Bacteroides merdae, 81
Bacteroides ovatus, 81
Bacteroides thetaiotamicron, 81
Bacteroides uniformis, 81
Bacteroides vulgatus, 81
Bam HI, 93
Benzoate, 116
Benzylpenicillin
  degradation of to benzylpenicilloic acid, 213
  Supplement C and, 213
Benzylpenicilloic acid
  degradation of benzylpenicillin to, 213
Bg1 II, 96
Bile
  lomefloxacin metabolites in, 222
Bleeding esophageal varices, 131
Blood
  agar, 131
  sheep, 135
Bone marrow transplantation
  cytomegalovirus pneumonitis and, 205
  varicella zoster virus antibodies and, 61
Brain heart infusion broth, 81
Branhamella catarrhalis
  fatty acid and lipopolysaccharide analysis of atypical strain in blood culture, 130
Breakpoints
  agar dilution method, 49
  penicillin, 49
Broncheolar lavage fluid
  centrifugation cultures of for diagnosis of cytalomegalovirus pneumonitis, 205
Bronchial aspirate
  Legionella pneumophila detection in, 125
Broth microdilution test
  Chromobacterium violaceum susceptibility pattern prediction and, 31
Brucella agar, 135
Butzler's antibiotic supplement, 135

Campylobacter growth supplement, 135
Candida albicans
  DNA probes for, 171
Candidiasis, 171
Caprate, 195
Caproate, 195
Caprylate, 195
Carbon dioxide, 131
Carcinoma
  cervical, 23
  hepatocellular, 240
  penile, 23
Cardiac system
  Mycoplasma pneumoniae infection in, 109
Casein, 116
Catalase, 131
  Rhodococcus detection and, 187
Catheters
  peripheral venous, 57
Cats
  Rhodococcus infection in, 185
Cattle
  sero group C streptococcal infection in respiratory mucosa of, 181
CBre3-enzyme immunoassay, 103
Cefaclor
  Supplement C and, 213
Cefamandole
  against *Chromobacterium violaceum*, 33
Cefazolin
  for *Aeromonas* suppurative thrombophlebitis, 57
  for cellulitis, 115
  MICs for, 58
  against *Staphylococcus aureus*, 146
  Supplement C and, 213
Cefoperazone
  for *Aeromonas* suppurative thrombophlebitis, 58
Cefotetan
  against *Chromobacterium violaceum*, 31
Cefoxatime
  for *Aeromonas* suppurative thrombophlebitis, 58
  against *Bacteroides fragilis* group, 81
  against *Chromobacterium violaceum*, 33
  MBCs for, 81
  metabolite, 81
  MICs for, 81
  against *Nocardia brasiliensis*, 117
Cefoxitin
  against *Chromobacterium violaceum*, 33
  against *Neisseria gonorrhoeae*, 49
Ceftazidime
  for *Aeromonas* suppurative thrombophlebitis, 58
Ceftizoxime
  against *Chromobacterium violaceum*, 33
  against *Nocardia brasiliensis*, 117

Ceftriaxone
against *Chromobacterium violaceum*, 33
against *Neisseria gonorrhoeae*, 49
against *Nocardia brasiliensis*, 117
Cell culture
for cytomegalovirus detection, 121
glutaraldehyde fixed, 61
Cells
bacterial, immunogold labelling of, 7
Cellulitis
cefazolin for, 115
group C *Streptococcus*-caused, 181
Centers for Disease Control (CDC)
definition for AIDS, 1
guidelines on *Neisseria gonorrhoeae*, 49
Central nervous system. See CNS
Centrifugation cultures
broncheolar lavage fluid for cytalomegalovirus pneumonitis diagnosis, 205
shell viral for cytomegalovirus detection, 121
Cephalosporin
against *Chromobacterium violaceum*, 31
penicillin resistance to, 145
Cephalothin
against *Chromobacterium violaceum*, 33
Supplement C and, 213
Cephamycin
against *Chromobacterium violaceum*, 31
Cervical carcinoma, 23
Cervix
intraepithelial neoplasia of, 23
invasive cancer of, 23
Chicken erythrocytes, 136
Chloramphenicol
against *Chromobacterium violaceum*, 31
Cholera toxin, 137
Chromobacterium violaceum
amikacin against, 31
aminoglycosides against, 31
apalcillin against, 31
aztreonam against, 31
cefamandole against, 33
cefotaxime against, 33
cefotetan against, 31
cefoxitin against, 33
ceftizoxime against, 33
ceftriaxone against, 33
cephalosporin against, 31
cephalothin against, 33
cephamycin against, 31
chloramphenicol against, 31
ciprofloxacin against, 31
clavulanic acid/ticarcillin against, 31
doxycycline against, 31
gentamicin against, 31
imipenem against, 31
mezlocillin against, 31
nalidixic acid against, 33
norfloxacin against, 31
pefloxacin against, 31
piperacillin against, 31
rifampin against, 31
ticarcillin against, 31
tobramycin against, 31
trimethoprim-sulfamethoxazole against, 31
vancomycin against, 31
Chromogenic cephalosporin filter paper disc test
Supplement C and, 213
Chromosomal resistance
tetracycline and, 49
Chromosomes
Shigella spp., 75
Chronic granulomatous disease, 31
Ciprofloxacin
against *Chromobacterium violaceum*, 31
against *Nocardia brasiliensis*, 117
lomefloxacin and, 221
Citrate, 116
Clavulanic acid
Supplement C and, 213
Clavulanic acid/ticarcillin
against *Chromobacterium violaceum*, 31
Clindamycin
for *Staphylococcus aureus*, 145
Clostridium difficile
-associated diarrhea, 85
Cloxacillin
against *Staphylococcus aureus*, 145
C-methyl, 221
CNS
Mycoplasma pneumoniae infection in, 109
Co-agglutination
for antigen detection, 7
Cocci
gram-negative, 133
Cold agglutinin test
Mycoplasma pneumoniae isolation using, 109
Colitis
Clostridium difficile-associated, 86
Colonic
diverticulosis, 58
mucosal secretion in monkeys, 75
Common warts
human papillomavirus DNA and, 93
Community-acquired pneumonia, 7
Complement fixation test (CFT)
Mycoplasma pneumoniae antibody and, 109
varicella zoster virus antibodies, and 61
Condylomata acuminata
anogenital, 24
human papillomavirus DNA in, 23
urethral, 23
Conjugates
antimouse immunogold, 7
Corneal ulcer
Rhodococcus rodochrous isolation from, 188
Corticosteroid therapy
as potential risk factor for *Aeromonas* spp. infection, 57
Corynebacterium spp., 185
Cotrimoxazole
against *Staphylococcus aureus*, 146
Counterimmunoelectrophoresis
for antigen detection, 7
C polysaccharide, pneumococcal (Pnc)
cross-reactions between α-streptococci and, 7
Cross-reactions
between pneumococci and α-streptococci, 7
Cryptosporidium spp., 136
Culturette brand (CDT) latex testing
for *Clostridium difficile*-associated diarrhea diagnosis, 85
Cutaneous mycobacteriosis, 114
Cytomegalovirus
detection of using shell viral centrifugation and conventional cell culture, 121
Cytomegalovirus pneumonitis
centrifigation cultures of broncheoalveolar lavage fluid for diagnosis of, 205
Cytotoxin
testing for *Clostridium difficile*-associated diarrhea diagnosis, 85
toxin B, 86
toxin D-2, 86

Degradation
benzylpenicillin to benzylpenicilloic acid, 213

Desacetylcefoxatime
against *Bacteroides fragilis* group, 81
Diabetes mellitus, 115
Diarrhea
Clostridium difficile-associated, 85
nontoxigenic 01 *vibrio cholerae* associated with, 134
trimethoprim-sulfamethoxazole for, 136
Diarrheal surveillance studies, 135
Dieterle silver stain, 125
Difloxacin
lomefloxacin and, 221
Difluoro-quinolone, 221
Diplococci
gram-negative, 131
Direct antimicrobial drug susceptibility testing of *Mycobacterium tuberculosis* using radiometric method, 41
Disk diffusion susceptibility test
Chromobacterium violaceum susceptibility pattern prediction and, 31
Diverticulosis
colonic, 58
DNA
Aspergillus fumigatus, 172
Bacillus subtilis, 172
Candida albicans, 171
fungal, 171
HPV 6/11-related, 23
HPV 6a, 23
HPV 11a, 23
HPV 16, 23
human papillomavirus, 23, 93
hybridization techniques, 23
mouse 3T3, 172
probe for detection of *Mycoplasma pneumoniae*, 109
probes for *Candida albicans*, 171
Pseudomonas syringae, 172
yeast, 171
DNase, 131
Dorset egg slant, 185
Dot blot hybridization assay
human papillomavirus DNA and, 93
Doxycycline
against *Chromobacterium violaceum*, 31
against *Nocardia brasiliensis*, 116

EcoRI, 96
Elastase
production in clinical isolates of *Aspergillus* spp., 165
Electron microscopy
demonstration of cross-reactions between pneumococci and α-streptococci using, 7
ELISA immunoassay
Merck, 149
pneumococcal antigen detection by, 7
screening of antibodies to varicella zoster virus in leukemic patients and, 61
Shigella spp. detection by, 75
Endocarditis
aminoglycosides for, 139
gentamicin for, 139
penicillin for, 139
in rabbits, 139
rifampin for, 139
Streptococcus-caused, 139
streptomycin for, 139
vancomycin for, 139
Endonucleases, 93
restriction, 171
Enoxacin
lomefloxacin and, 221
Enteritis
Aeromonas spp.-caused, 57
Enterobacteriaceae
spontaneous mutation to lomefloxacin resistance and, 221
Enterotoxin
assays, 136
toxin A, 86
toxin D-1, 86
Enzyme linked immunosorbent assays (EIA)
HIV-1 and, 159
Epithelium
benign growths of, 93
malignant transformation of, 93
Erythema
Nocardia brasiliensis infection and, 114
penicillin for, 115
Erythritol, 116
Erythrocytes
chicken, 136
Erythromycin
against *Nocardia brasiliensis*, 119
against *Staphylococcus aureus*, 145
Escherichia coli
oligonucleotide probe for heat-labile toxin of, 135
Esculin
Rhodococcus detection and, 187
Esophogeal varices
bleeding, 131
Esterase
characterization of *Aeromonas* spp. using, 195
Ethambutol
against *Mycobacterium tuberculosis*, 45
Ethyl acetate, 136
1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid hydrochloride, 221
Eye
Rhodococcus infection of, 185

Fasciotomy, 58
Fatty acid
analysis of atypical *Branhamella catarrhalis* strain in blood culture, 131
Females
condyloma acuminata in, 23
Fibroblast monolayer toxicity
shell vial centrifugation and, 121
Fibroblasts
foreskin, 149
Filiform warts
human papillomavirus DNA and, 93
Fleroxacin
lomefloxacin and, 221
Flow cytometry
practical, 190
Flucloxacillin
against *Staphylococcus aureus*, 145
Fluorescent antibody to membrane antigen test (FAMA) for detection of varicella zoster virus antibodies, 61
Fluorochrome staining
Mycobacterium tuberculosis and, 41
Fluoroimmunoassay
screening of antibodies to varicella zoster virus in leukemic patients and, 61
Foals
Rhodococcus-induced pneumonia in, 185
Foreskin fibroblast tube culture system, 149
Formalin, 136
Foxes
sero group C streptococcal infection in respiratory mucosa of, 181
Fructose, 131
Fungal DNA, 171
Fungi. See specific organisms

Galactose, 116

β-Galactosidase, 131
Gamma-glutamylamino-peptidase, 13
Gastrointestinal disease
  Clostridium difficile-associated, 85
Gelatin
  Rhodococcus detection and, 187
Genetic heterogeneity
  human papillomavirus, 93
Genital tract
  viral types infecting, 93
Genital warts. See Condylomata acuminata
Genome
  human papillomavirus, 23, 93
Gentamicin
  for *Aeromonas* suppurative thrombophlebitis, 58
  against *Chromobacterium violaceum*, 31
  for endocarditis, 139
  against *Nocardia brasiliensis*, 117
  against *Staphylococcus aureus*, 146
Gerbils
  sero group C streptococcal infection in respiratory mucosa of, 181
Giemsa stained smears
  of bronchial aspirate and *Legionella pneumophila* detection in, 125
Glucose, 116, 131
Glucuronide, 222
Gold-labelled antibodies
  demonstration of cross-reactions between pneumococci and α-streptococci using, 7
Gordona spp., 185
Glutaraldehyde, 61
Gonococcal Isolate Surveillance Project, 49
Granulomatous disease
  chronic, 31
Guinea pigs
  sero group C streptococcal infection in respiratory mucosa of, 181

Haemophilus influenzae
  antimicrobial susceptibility testing of, 213
  type b, 8
Health care workers
  HIV infection of, 103
Heat inactivation
  inactivation effects on HIV antibody screening and confirmatory test systems, 103
  as symptom of *Aeromonas* suppurative thrombophlebitis, 57
Hektoen enteric agar, 135
Hematologic malignancy
  as risk factor for *Aspergillus* infection, 165
Hemin, 213
β-Hemolysis, 133
Hepadna viruses
  animal, 241
Hepatitis
  A (HAV), 241
  B (HBV), 241
  delta virus (HDV), 241
  non-A non-B (ETNANB), 241
  viral, liver disease and, 241
Hepatocellular carcinoma, 241
High pressure liquid chromatography (HPLC)
  benzylpenicillin and, 213
  cefotaxime and, 81
Hinc II, 96
HIV Novapath Immunoblot Assay, 159
HIV. See Human immunodeficiency virus
Horseradish peroxidase technique
  human papillomavirus antiserum identification by, 23
Horses
  sero group C streptococcal infection in respiratory mucosa of, 181
HTLV-III. See Human T cell lymphotropic virus type-III
Human immunodeficiency virus (HIV)
  antibody screening, 103
  commercially developed indirect immunofluorescence system for detection of antibodies against, 159
  confirmatory tests for, 103
  effects of heat inactivation on, 103
  EIA for detection of, 159
  indirect immunofluorescence for detection of, 159
  radioimmunoprecipitation for detection of, 159
  Western blot analysis for detection of, 159
Human nocardiosis, 113
Human papillomavirus (HPV)
  antiserum identification by horseradish peroxidase technique, 23
  DNA in condylomata acuminata from Japanese males, 23
  genetic heterogeneity of, 93
  genomic types, 93
  HPV1, 93
  HPV1a, 93
  HPV2, 93
  HPV2a, 93
  in skin warts, 93
Humans
  sero group C streptococcal infection in respiratory mucosa of, 181
Human T cell lymphotropic virus type-III (HTLV-III)
  screening assays for, 103
Hydration
  intravenous, 57
L-Hydroxyproline, 195
Hypertension, 115
Hypotension
  refractory, 58
Hypoxanthine, 116

^{125}I, 111
IgA, 75
IgG, 75
IgM, 75, 111
Imipenem
  against *Chromobacterium violaceum*, 31
  against *Nocardia brasiliensis*, 117
Imipenem-cilastin
  for *Aeromonas* suppuratative thrombophlebitis, 58
Immune status
  varicella zoster virus, 148
Immunoassays
  CBre3 enzyme, 103
  ELISA, 61, 149
  enzyme (EIA), for antigen detection, 7
  indirect immunofluorescence, 159
  radioprecipitation, 159
Immunoblot analysis
  Shigella spp. and, 75
Immunocompetent patients
  human nocardiosis in, 113
Immunocompromised patients
  Aspergillus infection in, 165
  candidiasis in, 171
  cytomegalovirus pneumonitis in, 205
  human nocardiosis in, 113
  mycobacterial infections in, 1
  Rhodococcus rhodocrous infection in, 185
Immunofluorescence assay
  for detection of HIV-1 antibodies, 159
Immunogold labelling
  of bacterial cells, 7
Immunosuppressive therapy
  as high-risk factor for varicella zoster virus infection, 61
Indirect immunofluorescence system

for detection of HIV-1 antibodies, 159
Indirect susceptibility testing
of *Mycobacterium tuberculosis*, 41
Infection
actinomycotic mycetoma, 113
Aspergillus spp., 165
Candida albicans, 171
gram-positive, 139
hepatitis B virus, 240
Mycoplasma pneumoniae, 109
Nocardia brasiliensis, 113
nosocomial, 61
puerpural, 181
pulmonary opportunistic, 205
Rhodococcus rhodocrous, 185
sero group C streptococcal in intravenous drug abusers, 180
Shigella spp., 75
soft tissue, 57
urinary tract, 181
Inositol, 116
Insulin
for temporal arthritis, 115
Interstitial lung disease, 205
Intraepithelial neoplasia
cervical, 23
Intravenous
catheter-related phlebitis, 57
drug users and sero group C streptococcal infection in, 181
hydration, 57
Invasive aspergillosis, 165
Isoniazid
against *Mycobacterium tuberculosis*, 45
Isoxazolyl penicillin, 145

Japanese males
human papillomavirus DNA in condylomata acuminata from, 23
Jensenia spp., 185

Kanamycin
against *Nocardia brasiliensis*, 117
Kinyoun acid-fast stain, 116

β-Lactamase, 131
antagonists in Supplement C, 213
Neisseria gonorrhoeae production of, 49
-producing gram-negative bacilli, 221
staphylococcal, 145
ticarcillin induction of, 31
Lactose, 116
Latex
agglutination for antigen detection, 7
testing for *Clostridium difficile*-associated diarrhea diagnosis, 85
Legionella pneumophila
detection of in bronchial aspirate, 125
sero group 1, 125
Legionella spp., 111
Legionnaire's disease
pulmonary complications and, 125
L-Leucyl-L-alanine, 195
Leukemia
screening of antibodies to varicella zoster virus in, 61
Leukocyte count
Aeromonas suppurative thrombophlebitis and, 58
Lincomycin
against *Staphylococcus aureus*, 145
Lincosamides
against *Staphylococcus aureus*, 145
Lipopolysaccharide
analysis of atypical *Branhamella catarrhalis* strain in blood culture, 131
Liver disease
viral hepatitis and, 241
Lomefloxacin
ciprofloxacin and, 221
difloxacin and, 221
enoxacin and, 221
fleroxacin and, 221
MBCs for, 222
MICs for, 221
multicenter in vitro evaluation of, 221
norfloxacin and, 221
NY-198, 221
ofloxacin and, 221
penicillin and, 222
SC-4711, 221
susceptibility testing, 221
tetracycline and, 222
Lung biopsy
for diagnosis of opportunistic pulmonary infections, 205
Lymphangitis, 115
Lymphocutaneous infection
Nocardia brasiliensis, 113
L-Lysine, 195
Lysozyme, 116

MacConkey agar, 131, 135
Macrolides
against *Staphylococcus aureus*, 145
Macrophages, 125
Malate, 116
Males
human papillomavirus DNA in condylomata acuminata from, 23
Malignant disorders
hematologic, 165
as high-risk factor for varicella zoster virus infection, 61
Maltose, 116, 131
Mannitol, 116
Medrol
for chronic pulmonary disease, 58
Meningitis
Streptococcus-caused, 7, 181
Merthiolate-iodine-formaldehyde (MIF), 136
Metabolic acidosis
Aeromonas suppurative thrombophlebitis and, 58
Methicillin
against *Nocardia brasiliensis*, 118
-resistant *Staphylococcus aureus* (MRSA), 145
Methyl-D-glucoside, 116
Mezlocillin
for *Aeromonas* suppurtative thrombophlebitis, 59
against *Chromobacterium violaceum*, 31
Mice
Aspergillus-induced pneumonia in, 165
Rhodococcus infection in, 185
Minimal inhibitory concentrations (MICs)
for ampicillin, 58, 213
for cefazolin, 58
for cefotaxime, 81
for lomefloxacin, 221
for rifampin, 141
for spectinomycin, 49
for Supplement C, 213
for vancomycin, 141
Minimum bactericidal concentration (MBC)
cefotaxime, 81
lomefloxacin, 222
rifampin, 141
vancomycin, 141
Minocycline
against *Nocardia brasiliensis*, 117
Monkeys
colonic mucosal secretions from after *Shigella* infections, 75
Monoclonal antibodies
gold-labelled, demonstration of cross-reactions between pneumococci and α-streptococci using, 7

against viral antigens, 206
MOTT bacilli, 67
Mouse 3T3 DNA, 172
Moxalactam
for *Aeromonas* suppurative thrombophlebitis, 58
Msp I/Hpa II restriction analysis
human papillomavirus DNA and, 93
Mueller–Hinton
agar, 213
broth, 213
Multiple organ abscesses
Chromobacterium violaceum-caused, 31
Mycetoma
actinomycotic, 113
Mycobacteria
primary isolation of, 1
Mycobacteriosis
cutaneous, 114
disseminated, 1
Mycobacterium africanum, 67
Mycobacterium avium complex
improved detection of with Bactec radiometric system, 1
Mycobacterium bovis, 67
Mycobacterium complex
differentiation of from mycobacteria other than *M. tuberculosis*, 67
Mycobacterium kansasii, 67
Mycobacterium rhodococcus, 185
Mycobacterium spp., 185
Mycobacterium tuberculosis
direct antimicrobial drug susceptibility testing of using radiometric method, 41
ethambutol against, 45
identification of in sputum, 67
isoniazid against, 45
primary isolation of, 1
rifampin against, 45
streptomycin against, 45
Mycoplasma genitalium, 111
Mycoplasma pneumoniae
antibody, 109
DNA probe vs. culture for detection of, 109
Mycoplasma spp.
primary atypical pneumonia, 109

NAD, 213
Nafcillin
against *Staphylococcus aureus*, 145
Nalidixic acid
against *Chromobacterium violaceum*, 33
Nasogastric suction, 57
Nausea
as symptom of *Aeromonas* suppurative thrombophlebitis, 57
Neisserria gonorrhoeae
agar dilution method and, 49
antimicrobial agent resistance in, 49
cefoxitin against, 49
ceftriaxone against, 49
β-lactamase production by, 49
spectinomycin against, 49
tetracycline against, 49
Neisseria meningitidis
antisera, 131
Neutrophil disorders
underlying, 31
Nitrate, 116, 131, 187
Nitrite, 131
p-Nitro-alpha-acetyl-amino-β-hydroxypropriophenone (NAP), 67
Nitrocellulose filters, 172
Nocardia asteroides, 116
Nocardia brasiliensis
amikacin against, 117
aminocyclitols against, 119
ampicillin against, 117
augmentin against, 117
cefotaxime against, 117
ceftizoxime against, 117
ceftriaxone against, 117
ciprofloxacin against, 117
doxycycline against, 116
erythromycin against, 119
gentamicin against, 117
imipenem against, 117
kanamycin against, 117
methicillin against, 118
minocycline against, 117
potassium iodide against, 117
primary lymphocutaneous infection of, 113
sporitrichoid, 113
sulfa drugs against 119
sulfadiazine against, 118
sulfadizine against, 115
sulfamethoxazole against, 114
sulfonamides against, 119
surgery against, 118
tetracycline against, 118
tobramycin against, 117
trimethoprim against, 114
Trimethoprim/sulfa against, 117
triple sulfa against, 118
Nocardia caviae, 116
Nocardia spp., 185
Nocardiosis
human, 113
Nonanoate, 195
Non-A non-B hepatitis (ETNANB), 241
Nongonoccocal urethritis, 111
Norfloxacin
against *Chromobacterium violaceum*, 31
lomefloxacin and, 221
Nosocomial infections
in oncologic units, 61
Nucleotide pairs
human papillomavirus DNA genome, 93
NY-198 lomefloxacin
multicenter in vitro evaluation of, 220

Ofloxacin
lomefloxacin and, 221
Oleic acid, 133
Oligonucleotide probe
for heat-labile toxin of *Escherichia coli*, 135
Omniserum
demonstration of cross-reactions between pneumococci and α-streptococci using, 8
Osidase
characterization of *Aeromonas* spp. using, 195
Oxacillin
for phlebitis, 57
against *Staphylococcus aureus*,145
Oxidase, 133
Rhodococcus detection and, 187

^{32}P, 171
Pain
abdominal, 57
as symptom of *Aeromonas suppurative* thrombophlebitis, 57
Palmitoleic acid, 133
Papillomaviruses
antisera to, 23
Papovaviridae, 93
pBR322, 93
Pefloxacin
against *Chromobacterium violaceum*, 31
Penicillin
aminoglycoside-resistant, 145
breakpoints, 49
cephalosporin-resistant, 145
contaminated β-lactamase directed to, 213
for endocarditis, 139
for erythema, 115
isoxazolyl, 145
lomefloxacin and, 222
against *Neisseria gonorrhoeae*, 49
penicillinase-resistant, 145
for phlebitis, 57
semisynthetic, 146
Penicillinase

-producing *Neiseria gonorrhoeae*, 49
-resistant penicillin, 145
Penile carcinoma, 23
Pentasaccharides, 8
Peptidase
characterization of *Aeromonas* spp. using, 194
Peptone water broth, 135
Peripheral vascular disease, 115
Peripheral venous catheters
Aeromonas suppurative thrombophlebitis as consequence of using, 57
Peru
nontoxigenic 01 *Vibrio cholerae* in, 135
Phlebitis
cefazolin for, 57
intravenous catheter-related, 57
oxacillin for, 57
penicillin for, 57
Phosphorylcholine, 7
Piglets
Rhodococcus infection in, 185
Piperacillin
for *Aeromonas* suppurative thrombophlebitis, 58
against *Chromobacterium violaceum*, 31
Piperazine ring, 221
Plantar warts
human papillomavirus DNA and, 93
Plasmid-encoded antigens
serological response to in patients with shigellosis, 75
Plasmids
pBR322, 93
Pneumococcal
capsular antigens, 8
C-polysaccharide (PnC), cross-reactions between α-streptococci and, 7
Pneumonia
Aspergillus-induced in mice, 165
Community-acquired, 7
group C *Streptococcus*-caused, 181
Mycoplasma primary atypical, 109
Rhodococcus-induced, 185
Pneumonitis
cytalomegalovirus, 205
Polyclonal antibodies
gold-labelled, demonstration of cross-reactions between pneumococci and α-streptococci using, 7
Polymorphonuclear leukocytes
Aeromonas suppurative thrombophlebitis and, 58
Polymyxin B, 136
Polypeptide antigens
after *Shigella* infections, 75
Polysaccharides, 131
type 1 capsular, 8
Potassium iodide
against *Nocardia brasiliensis*, 117
Potential risk factors
for *Aeromonas* spp. infection, 57
Practical flow cytometry, 190
Prednisone
for chronic pulmonary disease, 57
for temporal arthritis, 115
L-Proline, 195
Prolylamino peptidase, 131
Pseudomonas syringae
DNA, 172
PstI, 96
cleavage pattern, 23
Puerpural infection
group C *Streptotoccus*-caused, 181
Pulmonary disease, 205
medrol for, 58
prednisone for, 57
Puncture wounds
human nocardiosis infection via, 113
Pvu II, 96

4-Quinolone, 221

Rabbits
endocarditis in, 139
Radioimmunoprecepitation immunoassay, 159
Radiometric method
direct antimicrobial drug susceptibility testing of *Mycobacterium tuberculosis* by, 41
Raffinose, 116
Refractory hypotension
Aeromonas suppurative thrombophlebitis and, 58
Respiratory acidosis
Aeromonas suppurative thrombophlebitis and, 58
Respiratory disease
acute lower, 111
Respiratory mucosa
sero group C *Streptococcal* infection in, 181
Respiratory specimens
Mycoplasma pneumoniae detection in, 109
Respiratory tract, upper
Streptococcus pneumoniae as pathogen in infection of, 7
Restriction endonuclease
Candida albicans DNA and, 171
Restriction maps
human papillomavirus DNA, 93
Rhamnose, 116
Rhodococcus rhodochrous
isolation from chronic corneal ulcer, 185
Ribitol phosphate, 8
Rifampin
against *Chromobacterium violaceum*, 31
for endocarditis, 139
MICs, for 141
against *Mycobacterium tuberculosis*, 45
time kill curve analysis of, 138
RNA
ribosomal in *Mycoplasma pneumoniae*, 111
Rodents
sero group C streptococcal infection in respiratory mucosa of, 181
Rose bengal-elastin agar, 165

Salt broth, 137
Saprophytes. See specific bacilli
SC-4711 lomefloxacin
multicenter in vitro evaluation of, 221
Screening
HIV antibody, 103
Selenite broth, 135
Septicemia
Chromobacterium violaceum-caused, 31
Sero group 1
Legionella pneumophila, 125
Sero group C streptococcal infection
in intravenous drug abusers, 181
Sexually transmitted diseases (STDs). See specific diseases
Sheep
blood, 135
sero group C streptococcal infection in respiratory mucosa of, 181
Shell viral centrifugation
for cytomegalovirus detection, 121
Shigella flexneri
M90T water-extracted antigens and, 75
Shigella spp.
plasmid-encoded antigens of virulent, 75
Shigellosis

serological response to plasmid-encoded antigens in patients with, 75
Skin warts
human papillomavirus in, 93
Small bowel obstruction, 57
Sodium
chloride, 136, 146
nitrite, 131
Soft tissue infection
Aeromonas spp.-caused, 57
Soil saprophytes. See specific bacilli
Sorbitol, 116
Southern blot hybridization
human papillomavirus genome isolation by, 23
Spectinomycin
against *Neisseria gonorrhoeae*, 49
MICs for, 49
Sporotrichosis, 113
Sputum
identification of *Mycobacterium tuberculosis* in, 67
Staphylococcal
β-lactamase, 145
Staphylococcus aureus
cefazolin against, 146
clindamycin against, 145
cloxacillin against, 145
cotrimoxazole against, 146
erythromycin against, 145
flucloxacillin against, 145
gentamicin against, 146
lincomycin against, 145
lincosamides against, 145
macrolides against, 145
methicillin-resistant (MRSA), 145
nafcillin against, 145
oxacillin against, 145
vancomycin against, 145
Staphylococcus rhodocrous. See *Rhodococcus rhodocrous*
Staphylococcus spp.
lymphangitis due to, 115
Streptococcal infection
sero group C in intravenous drug abusers, 181
Streptococcus spp.
cross reactions between pneumococci and, 7
endocarditis due to, 139
lymphangitis due to, 115
nutritionally deficient, 139
rifampin against, 139
sulphydryl compound-requiring, 139
vancomycin against, 139
Streptococcus pneumoniae
as pathogen, 7
diagnostic tests for, 7
Streptomycin
for endocarditis, 139
against *Mycobacterium tuberculosis*, 45
String test, 136
Succinate, 116
Sucrose, 131
Sulfadiazine
against *Nocardia brasiliensis*, 115
Sulfamethoxazole
against *Nocardia brasiliensis*, 114
Sulfonamides
against *Nocardia brasiliensis*, 119
Sulphydryl compounds, 139
Supplement C (SC)
acidimetric testing and, 213
benzylpenicillin and, 213
cefaclor and, 213
cefazolin and, 213
cephalothin and, 213
characterization of β-lactam antagonist in, 213
clavulanic acid and, 213
MICs for, 213
Suppurative thrombophlebitis due to *Aeromonas* spp., 57
amikacin for, 58
ampicillin for, 58
cefazolin for, 58
cefoperazone for, 58
cefotaxime for, 58
ceftazidime for, 58
gentamicin for, 58
imipenem-cilastin for, 58
mezlocillin for, 58
moxalactam for, 58
piperacillin for, 58
symptoms of, 57
tobramycin for, 58
trimethoprim-sulfamethoxazole for, 58
Surgery
against *Nocardia brasiliensis*, 118
Swelling
Aeromonas suppurative thrombophlebitis and, 57
Nocardia brasiliensis infection and, 114
Swine
sero group C streptococcal infection in respiratory mucosa of, 181
Synergy
cefotaxime and desacetylcefotaxime against *Bacteroides fragilis* group, 81
rifampin with vancomycin, 140

TCBS agar, 136
Temporal arthritis
insulin for, 115
prednisone for, 115
Tetracycline
against *Chromobacterium violaceum*, 31
chromosomal resistance and, 49
against *Neisseria gonorrhoeae*, 49
against *Nocardia brasiliensis*, 118
lomefloxacin and, 222
Tetramethyl-p-phenylene diamine hydrochloride, 131
Thai populations
immunological response to plasmid-encoded antigens of *Shigella* spp. in, 75
Thayer–Martin agar, 131
Theophylline, 57
Thrombophlebitis
suppurative due to *Aeromonas* spp., 57
Ticarcillin
against *Chromobacterium violaceum*, 31
clavulanic acid induction by, 31
Time kill curve analysis
of vancomycin and rifampin, 139
Tobramycin
against *Aeromonas* suppurative thrombophlebitis, 58
against *Chromobacterium violaceum*, 31
against *Nocardia brasiliensis*, 117
Tonsillitis
group C *Streptococcus*-caused, 181
Toxicity
fibroblast monolayer, 121
Transplantation
bone marrow, 61, 205
Tributyrin test, 131
Trimethoprim
against *Nocardia brasiliensis*, 114
Trimethoprim-sulfamethoxazole
against *Aeromonas* suppurative thrombophlebitis, 59
against *Chromobacterium violaceum*, 31
for diarrhea, 136
against *Nocardia brasiliensis*, 117
Triple sulfa
against *Nocardia brasiliensis*, 118
TSA/AMP agar, 136

Type 1 capsular polysaccharide, 8
Tyrosine, 116

Underlying neutrophil disorders, 31
Upper respiratory tract
  Streptococcus pneumoniae as pathogen in infections of, 7
Urea
  Rhodococcus detection in, 187
Urethral
  condylomata acuminata, 23
Urethritis
  nongonoccocal, 111
Urinary tract infection
  group C *Streptococcus*-caused, 181
Urine
  lomefloxacin metabolites in, 222

Vaccines
  hepatitis B, 240
  varicella zoster virus, 61
Vancomycin
  against *Chromobacterium violaceum*, 31
  for endocarditis, 139
  MICs for, 141
  against *Staphylococcus aureus*, 145
  time kill curve analysis of, 139
Varicella zoster virus (VZV)
  acute, 149
  acyclovir against, 149
  antibodies, 149
  immune status, 149
  screening of antibodies to in leukemic patients, 61
  vaccine, 61
Vascular disease
  peripheral, 115
Venereal warts. See Condylomata acuminata
Vibrio cholerae
  diarrhea and, 137
  E1 Tor strain, 135
  nontoxigenic 01, 135
Vibrio fluvialis
  diarrhea and, 137
Vibrio parahemolyticus
  diarrhea and, 137
Vibriostatic agent 0129, 136
varicella zoster virus and, 149
Viral hepatitis
  liver disease and, 241
Virgo HIV indirect immunofluorescence immunoassay
  HIV-1 detection and, 159
Vomiting
  as symptom of *Aeromonas* suppurative thrombophlebitis, 57
VPI methodology
  Bacteroides fragilis group isolate identification using, 81

Warm tap water compresses
  as potential risk factor for *Aeromonas* spp. infection, 57
Warts
  common, 93
  filiform, 93
  human papillomavirus in skin, 93
  plantar, 93
Water
  Aeromonas spp.-contaminated, 57
  saprophytes, 31
Western blot analysis
  HIV antibodies and, 103, 159

Xanthine, 116
XLD agar, 136
Xylose, 116
Xylose-lysine-desoxycholate agar, 135

Y1-adrenal cell assays, 135
Yeast
  DNA, 171

Ziehl–Neelsen staining
  Mycobacterium tuberculosis and, 41
  Rhodococcus infection and, 187